DUSA Pharmaceuticals, Inc. to Host First Quarter Financial Results and Corporate Highlights Conference Call

DUSA Pharmaceuticals, Inc. (NASDAQ GM: DUSA) announces that its corporate highlights and first quarter financial results press release will be issued on May 4, 2007 at 6:30 a.m. to be followed by a conference call at 8:30 a.m.

                Friday, May 4, 2007 - 8:30 a.m. Eastern
  If calling from the US or Canada use the following toll-free number:
                           800.647.4314
                          Password - DUSA

                  For International callers use
                           641.297.7663

            A recorded replay of the call will be available
                  North American callers 877.863.0350
                  International callers 858.244.1268

The call will be accessible on our web site approximately 1 hour following the call at www.dusapharma.com .

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc. is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 or Grade 2 actinic keratoses of the face or scalp, and is being studied for the treatment of acne. DUSA's other dermatology products include ClindaReach(TM) Nicomide® and the AVAR® line. DUSA is also researching additional indications for internal uses of Levulan PDT. DUSA is based in Wilmington, MA. Please visit the company's website at www.dusapharma.com for more information.

Contacts: DUSA Pharmaceuticals, Inc. Shari Lovell Director, Shareholder Services (416) 363-5059 Website: www.dusapharma.com